August 02, 2022
A District of Columbia federal judge on Tuesday awarded over $13 million in fees to Barrack Rodos & Bacine, Lowenstein Sandler LLP, and Murray Murphy Moul & Basil LLP for representing the investor class in a $65.75 million settlement of securities claims against drugmaker Mallinckrodt.
February 22, 2022
A Delaware bankruptcy judge on Tuesday approved a $65.75 million settlement resolving class claims that Mallinckrodt PLC concealed from investors its reliance on federal reimbursements for Acthar gel products.
November 19, 2018
Mallinckrodt PLC asked a D.C. federal judge to throw out a stockholder suit Monday, saying the investors can't meet a crucial legal test to show the firm deliberately misled them about reimbursement risks for the drug Acthar.
August 31, 2018
A group of Mallinckrodt PLC investors urged a D.C. federal judge Thursday to keep their consolidated complaint alive, arguing that the company knowingly issued false and misleading statements about one of its key drugs.
July 18, 2018
Mallinckrodt PLC and its top executives said Tuesday that investors knew of the antitrust risk linked to its infant seizure drug Acthar and have relied on "bad math" in accusing it of lying about the drug's dependence on federal revenue, urging a D.C. federal judge to put an end to the investors' suit.
March 12, 2018
A D.C. federal judge approved the State Teachers Retirement System of Ohio as lead plaintiff in a class action alleging Mallinckrodt PLC executives lied to shareholders about anti-competitive efforts, rejecting another plaintiff's "speculative" allegation that contributions to Ohio's attorney general leaves the pension's legal team vulnerable.
January 23, 2017
Just days after it reached a $100 million deal with the Federal Trade Commission and several states to end allegations it had snapped up a monopoly on infant seizure drug Acthar, Mallinckrodt PLC was hit with a proposed shareholder class action alleging executives had long concealed upcoming trouble.